[go: up one dir, main page]

NO20050060L - Medikament for behandling av overaktiv blaere - Google Patents

Medikament for behandling av overaktiv blaere

Info

Publication number
NO20050060L
NO20050060L NO20050060A NO20050060A NO20050060L NO 20050060 L NO20050060 L NO 20050060L NO 20050060 A NO20050060 A NO 20050060A NO 20050060 A NO20050060 A NO 20050060A NO 20050060 L NO20050060 L NO 20050060L
Authority
NO
Norway
Prior art keywords
medication
treatment
overactive bladder
overactive
pharmaceutically acceptable
Prior art date
Application number
NO20050060A
Other languages
English (en)
Norwegian (no)
Inventor
Nico J Visser
Hiroshi Kajii
Nobuyuki Takiguchi
Rian Van Meeteren
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of NO20050060L publication Critical patent/NO20050060L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20050060A 2002-06-07 2005-01-06 Medikament for behandling av overaktiv blaere NO20050060L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002166408 2002-06-07
PCT/JP2003/007149 WO2003103659A1 (fr) 2002-06-07 2003-06-05 Agent therapeutique pour le traitement de l'hyperactivite vesicale

Publications (1)

Publication Number Publication Date
NO20050060L true NO20050060L (no) 2005-03-04

Family

ID=29727628

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050060A NO20050060L (no) 2002-06-07 2005-01-06 Medikament for behandling av overaktiv blaere

Country Status (16)

Country Link
US (2) US20060035923A1 (fr)
EP (1) EP1552825A4 (fr)
JP (1) JP4466370B2 (fr)
KR (1) KR20050008795A (fr)
CN (1) CN100355419C (fr)
AR (1) AR040248A1 (fr)
AU (1) AU2003242166A1 (fr)
BR (1) BR0311414A (fr)
CA (1) CA2487899A1 (fr)
IL (1) IL165370A0 (fr)
MX (1) MXPA04012070A (fr)
NO (1) NO20050060L (fr)
PL (1) PL372560A1 (fr)
RU (1) RU2004135563A (fr)
TW (1) TW200408387A (fr)
WO (1) WO2003103659A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
ZA200608614B (en) * 2004-03-25 2008-06-25 Astellas Pharma Inc Composition for solid pharmaceutical preparation of solifenacin or salt thereof
PL2156824T3 (pl) * 2004-03-25 2013-03-29 Astellas Pharma Inc Kompozycja solifenacyny lub jej soli do zastosowania w formulacji stałej
EP1832288B1 (fr) * 2004-12-27 2012-06-20 Astellas Pharma Inc. Préparation pharmaceutique granulaire stable de solifénacine ou de son sel
ES2387571T3 (es) * 2004-12-27 2012-09-26 Astellas Pharma Inc. Composición farmacéutica granulada estable de solifenacina o de su sal
US20090131469A1 (en) * 2005-02-25 2009-05-21 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
KR20100040294A (ko) * 2007-07-20 2010-04-19 아스텔라스세이야쿠 가부시키가이샤 전립선 비대에 수반되는 하부 요로 증상의 개선용 의약 조성물
PT2216021E (pt) 2007-11-02 2012-11-06 Astellas Pharma Inc Composição farmacêutica para tratar uma bexiga hiperactiva
CA2709727A1 (fr) * 2007-12-21 2009-07-02 Astellas Pharma Inc. Composition pharmaceutique utilisee pour attenuer les symptomes du tractus urinaire inferieur
EP2181707A1 (fr) * 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Utilisation combinée d'un antagoniste de récepteur alpha-adrénergique et d'un agent anti-muscarinique
WO2010090172A1 (fr) * 2009-02-04 2010-08-12 アステラス製薬株式会社 Composition pharmaceutique pour une administration orale
US9119878B2 (en) * 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
KR102027912B1 (ko) * 2011-02-15 2019-10-02 지엘팜텍주식회사 경구투여용 탐술로신 또는 이의 약제학적으로 허용되는 염을 포함하는 서방성 삼중정제
WO2013142197A1 (fr) * 2012-03-19 2013-09-26 Wellesley Pharmaceuticals, Llc Formulation à libération prolongée pour réduire la fréquence de miction et son procédé d'utilisation
CN102743757A (zh) * 2012-07-09 2012-10-24 张家华 治疗膀胱流出道梗阻所致膀胱活动过度的药物
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
CN106265667B (zh) * 2015-05-18 2019-01-25 中国科学院生物物理研究所 一种氯喹的用途
CN106562968B (zh) * 2015-10-13 2019-08-13 南京华威医药科技集团有限公司 包含盐酸坦洛辛和琥珀酸索利那新的药物组合物
KR101879133B1 (ko) * 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
MX2022013103A (es) * 2020-04-27 2022-11-30 Zim Laboratories Ltd Nueva composicion farmaceutica multiparticulada de tamsulosina y solifenacina.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
TW536402B (en) * 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
TR200102583T2 (tr) * 1999-08-09 2002-07-22 Yamanouchi Pharmaceutical Co., Ltd. Alt idrar yolları semptomlarının tedavisine yönelik farmasötik bileşim.
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
AU2004227945B2 (en) * 2003-04-04 2006-10-26 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders

Also Published As

Publication number Publication date
CN1658859A (zh) 2005-08-24
US20070270459A1 (en) 2007-11-22
KR20050008795A (ko) 2005-01-21
CA2487899A1 (fr) 2003-12-18
PL372560A1 (en) 2005-07-25
EP1552825A1 (fr) 2005-07-13
EP1552825A4 (fr) 2009-11-25
US20060035923A1 (en) 2006-02-16
CN100355419C (zh) 2007-12-19
MXPA04012070A (es) 2005-03-07
BR0311414A (pt) 2005-03-15
TW200408387A (en) 2004-06-01
AR040248A1 (es) 2005-03-23
IL165370A0 (en) 2006-01-15
WO2003103659A1 (fr) 2003-12-18
AU2003242166A1 (en) 2003-12-22
JPWO2003103659A1 (ja) 2005-10-06
JP4466370B2 (ja) 2010-05-26
RU2004135563A (ru) 2005-06-10

Similar Documents

Publication Publication Date Title
NO20050060L (no) Medikament for behandling av overaktiv blaere
WO2003096979A3 (fr) Pharmacotherapie destinee a une maladie coeliaque
NO20032233L (no) Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer
AR044923A1 (es) Imidazoquinolinas sustituidas con sulfonamida
NO20044054L (no) Administrering av midler for behandling av betennelse
AU2003297621A1 (en) Medical devices for delivery of therapeutic agents
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
AR032293A1 (es) Estuche farmaceutico
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
MXPA05004697A (es) Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
NO20023111L (no) Utvortes preparat for behandling av pruritus
WO2006064228A3 (fr) Composes
AR022348A1 (es) Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior
AU2003281257A1 (en) A novel use of rapamycin and structural analogues thereof
NO20042586L (no) Behandlingsfremgangsmate
NO20054320L (no) Terapeutisk middel mot hemoroidesykdom
NO20064196L (no) Utvortes preparat for behandling av smertefulle hudskader
NO20054718L (no) Terapeutisk og/eller preventivt middel for kroniske hudsykdommer
HRP20050497B1 (hr) Uporaba levocetirizina za liječenje stalnog alergijskog rinitisa

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application